Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial

Abstract

Objective Daily aspirin, started in the first trimester of pregnancy, is commonly used for the prevention of preeclampsia and fetal growth restriction in multiple gestation. However, the optimal dose remains controversial and the evidence for the use of aspirin in multiple pregnancies is scarce. We aimed to estimate the impact of 80 mg of aspirin in twin pregnancies.

Study Design We performed a pilot double-blind randomized trial of women with twin pregnancies recruited between 8 and 14 weeks of gestation. Fifty participants (25 in each group) were randomized to 80 mg of aspirin daily at bedtime or a placebo from randomization until 36 weeks of gestation. Primary and secondary outcomes included the birth weight of live infants, preeclampsia, and aspirin responsiveness evaluated by a platelet aggregation test (platelet function assay [PFA]-100).

Results All participants were followed until birth, including 48 and 47 live newborns in the aspirin and the placebo groups, respectively. The mean birth weight difference between the aspirin (2,385 ± 529 g) and placebo (2,224 ± 706 g) groups was of 179 g (95% confidence interval [CI]: −172–531 g, p = 0.32). We observed two (8%) cases of preeclampsia in the aspirin group and no case with placebo (p = 0.49). Most importantly,16 of 24 participants who received aspirin (67%; 95% CI: 45–84%) had a normal PFA-100 test at 22 to 23 weeks, including the two cases of preeclampsia, suggesting that the majority of the participants were nonresponsive to 80 mg of aspirin.

Conclusion Our results suggest that the majority of women with twin pregnancies showed a lack of response to a daily dose of 80 mg of aspirin according to the PFA-100 test, compared with the expected 29% of nonresponsiveness in singleton pregnancies. A daily dose of 80 mg of aspirin is likely to be insufficient for the prevention of preeclampsia and other placenta-mediated complications in twin pregnancies.

Key Points

• Most women with twin pregnancies are nonresponsive to a daily dose of 80-mg aspirin.

• An 80 mg aspirin dose is insufficient to prevent placenta-mediated complications in twin pregnancies.

• Randomized trials using 100 to 160 mg of aspirin in twin pregnancies are needed.

Keywords

aspirin - preeclampsia - fetal growth restriction - twin pregnancy - prevention

Publikationsverlauf

Eingereicht: 05. Juni 2020

Angenommen: 02. März 2021

Artikel online veröffentlicht:
21. April 2021

• References

• 1 Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet 2016; 387 (10022): 999-1011
• 2 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics and the Society forMaternal-FetalMedicin. ACOG practice bulletin no. 204: fetal growth restriction. Obstet Gynecol 2019; 133 (02) e97-e109
• 3 Lawn JE, Blencowe H, Waiswa P. et al; Lancet Ending Preventable Stillbirths Series study group, Lancet Stillbirth Epidemiology investigator group. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 2016; 387 (10018): 587-603
• 4 Ton TGN, Bennett MV, Incerti D. et al. Maternal and infant adverse outcomes associated with mild and severe preeclampsia during the first year after delivery in the United States. Am J Perinatol 2020; 37 (04) 398-408
• 5 Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359 (01) 61-73
• 6 Leon LJ, McCarthy FP, Direk K. et al. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study. Circulation 2019; 140 (13) 1050-1060
• 7 Guerby P, Bujold E. Early detection and prevention of intrauterine growth restriction and its consequences. JAMA Pediatr 2020; 174 (08) 749-750
• 8 Sibai BM, Hauth J, Caritis S. et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Hypertensive disorders in twin versus singleton gestations. Am J Obstet Gynecol 2000; 182 (04) 938-942
• 9 Santana DS, Silveira C, Costa ML. et al; WHO Multi-Country Survey on Maternal and Newborn Health Research Network. Perinatal outcomes in twin pregnancies complicated by maternal morbidity: evidence from the WHO Multicountry Survey on Maternal and Newborn Health. BMC Pregnancy Childbirth 2018; 18 (01) 449
• 10 Ombelet W, Martens G, De Sutter P. et al. Perinatal outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study. Hum Reprod 2006; 21 (04) 1025-1032
• 11 Laine K, Murzakanova G, Sole KB, Pay AD, Heradstveit S, Räisänen S. Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: a population-based register study. BMJ Open 2019; 9 (07) e029908
• 12 Matthews KC, Fox NS, Rebarber A. The association between placental histopathology, fetal growth restriction, and preeclampsia in twin pregnancies. Am J Perinatol 2019
• 13 Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 110-120.e6
• 14 Loussert L, Vidal F, Parant O, Hamdi SM, Vayssiere C, Guerby P. Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat Diagn 2020; 40 (05) 519-527
• 15 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
• 16 Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36 (07) 575-576
• 17 Bergeron TS, Roberge S, Carpentier C, Sibai B, McCaw-Binns A, Bujold E. Prevention of preeclampsia with aspirin in multiple gestations: a systematic review and meta-analysis. Am J Perinatol 2016; 33 (06) 605-610
• 18 Bujold E, Roberge S, Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1): 402-414
• 19 Caron N, Rivard GE, Michon N. et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009; 31 (11) 1022-1027
• 20 Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36 (05) 416-441
• 21 Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy?. Eur J Obstet Gynecol Reprod Biol 2011; 157 (01) 38-42
• 22 Caspi E, Raziel A, Sherman D, Arieli S, Bukovski I, Weinraub Z. Prevention of pregnancy-induced hypertension in twins by early administration of low-dose aspirin: a preliminary report. Am J Reprod Immunol 1994; 31 (01) 19-24
• 23 Dumont A, Flahault A, Beaufils M, Verdy E, Uzan S. Effect of aspirin in pregnant women is dependent on increase in bleeding time. Am J Obstet Gynecol 1999; 180 (1 Pt 1): 135-140
• 24 Kalafat E, Shirazi A, Thilaganathan B, Khalil A. The role of aspirin in prevention of preeclampsia in twin pregnancies: does the dose matter?. Am J Obstet Gynecol 2020; 223 (03) 457-458